公开(公告)号：US20240360248A1

公开(公告)日：2024-10-31

申请号：US18684078

申请日：2022-08-17

申请人： NANOMAB TECHNOLOGY LIMITED

发明人： Chung Lim WONG ,  Hong Hoi TING

IPC分类号： C07K16/40 ,  G01N33/573 ,  G01N33/68

CPC分类号： C07K16/40 ,  G01N33/573 ,  G01N33/6854 ,  C07K2317/565 ,  C07K2317/569

摘要： Provided are a set of specific single-domain antibody coding sequences targeting PTK7 and an application thereof. The provided anti-PTK7 single-domain antibody may effectively bind to a PTK7 antigen, which provides a basis for the research and development of drugs targeting PTK7, including radionuclide drug conjugates, antibody drug conjugates, multispecific antibody drugs and so on.

公开(公告)号：US12129309B2

公开(公告)日：2024-10-29

申请号：US17736475

申请日：2022-05-04

申请人： Xencor, Inc.

发明人： Matthew Bernett ,  Gregory Moore ,  John Desjarlais ,  Seung Chu ,  Rumana Rashid ,  Umesh Muchhal

IPC分类号： C07K16/40 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  A61K39/00

CPC分类号： C07K16/40 ,  C07K16/18 ,  C07K16/2809 ,  C07K16/2896 ,  C07K16/3061 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/73 ,  C07K2317/92

摘要： The present invention is directed to heterodimeric antibodies that bind CD3 and CD38.

公开(公告)号：US12128061B2

公开(公告)日：2024-10-29

申请号：US16147844

申请日：2018-09-30

申请人： Vycellix, Inc.

发明人： Evren Alici

IPC分类号： A61K31/7105 ,  A61K9/127 ,  A61K31/7115 ,  A61K38/20 ,  A61P35/00 ,  C07K16/28 ,  C07K16/40 ,  C12N15/117

CPC分类号： A61K31/7105 ,  A61K9/1271 ,  A61K31/7115 ,  A61K38/2013 ,  A61P35/00 ,  C07K16/28 ,  C07K16/40 ,  C12N15/117 ,  C12N2310/17 ,  C12N2310/531 ,  C12N2320/30 ,  C12N2320/31 ,  C12N2320/32 ,  A61K31/7115 ,  A61K2300/00

摘要： The present invention comprises Rig I agonists for enhancing the effects of cytotoxic cells and stem Cells. The Rig I agonists can be used in vivo as small molecule therapeutics or in vitro to enhance cells for adoptive cell transfer. Applications include cancer therapy, immune system enhancement, chronic viral infection and treatment of viral induced inflammation and enhancement of virus based therapies.

公开(公告)号：US20240352152A1

公开(公告)日：2024-10-24

申请号：US18633379

申请日：2024-04-11

申请人： Omeros Corporation ,  University of Leicester

发明人： Gregory A. Demopulos ,  Hans-Wilhelm Schwaeble ,  Thomas Dudler ,  Larry W. Tjoelker

IPC分类号： C07K16/40 ,  A61K39/00 ,  A61P27/02 ,  A61P35/04

CPC分类号： C07K16/40 ,  A61P27/02 ,  A61P35/04 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

摘要： In one aspect, the present invention provides methods for preventing, treating, reverting and/or delaying angiogenesis in a mammalian subject suffering from, or at risk for developing, an angiogenesis-dependent disease or condition, comprising administering to the subject an amount of a MASP-2 inhibitory agent effective to inhibit angiogenesis. In some embodiments of these aspects of the invention, the MASP-2 inhibitory agent is a MASP-2 antibody or fragment thereof.

公开(公告)号：US12122848B2

公开(公告)日：2024-10-22

申请号：US17365723

申请日：2021-07-01

申请人： THE LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER

发明人： Omid Khorram ,  Tsai-Der Chuang

IPC分类号： C07K16/40 ,  A61K31/4188 ,  A61K31/4245 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/7105 ,  A61P15/00 ,  A61P19/04

CPC分类号： C07K16/40 ,  A61K31/4188 ,  A61K31/4245 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/7105 ,  A61P15/00 ,  A61P19/04

摘要： The present disclosure relates generally to compositions and methods for treating fibroid in a patient in need thereof, which entails administering to the patient an effective amount of an agent that inhibits the expression or activity of TDO2 or IDO1.

公开(公告)号：US12121525B2

公开(公告)日：2024-10-22

申请号：US17537786

申请日：2021-11-30

申请人： Sloan Kettering Institute for Cancer Research ,  Board of Regents, The University of Texas System

发明人： Jimmy Andrew Rotolo ,  Richard N. Kolesnick ,  Renata Pasqualini ,  Wadih Arap

IPC分类号： A61K31/55 ,  C07K16/28 ,  C07K16/40 ,  C07K16/44 ,  A61K39/00

CPC分类号： A61K31/55 ,  C07K16/28 ,  C07K16/40 ,  C07K16/44 ,  A61K2039/505

摘要： We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.

公开(公告)号：US20240342284A1

公开(公告)日：2024-10-17

申请号：US18593711

申请日：2024-03-01

申请人： Arsenal Biosciences, Inc.

发明人： Angela Boroughs ,  Levi Gray-Rupp ,  Samuel A. Williams ,  Zhen Jian Zhou ,  Matthew Drever ,  Duy Nguyen ,  Amy-Jo Casbon ,  Anzhi Yao ,  Thomas Gardner

IPC分类号： A61K39/00 ,  A61P35/00 ,  C07K14/725 ,  C07K16/30 ,  C07K16/40 ,  C12N9/22 ,  C12N15/11 ,  C12N15/90

CPC分类号： A61K39/464495 ,  A61K39/4631 ,  A61K39/464454 ,  A61P35/00 ,  C07K14/7051 ,  C07K16/3069 ,  C07K16/40 ,  C12N9/22 ,  C12N15/11 ,  C12N15/907 ,  C07K2317/31 ,  C12N2310/20

摘要： Provided herein are antibodies and chimeric priming receptors that bind PSMA and antibodies and chimeric antigen receptors that bind CA9. Also provided are systems of chimeric priming receptors that bind PSMA and chimeric antigen receptors that bind CA9, cells expressing such systems, and methods of use thereof.

公开(公告)号：US20240342278A1

公开(公告)日：2024-10-17

申请号：US18523203

申请日：2023-11-29

申请人： Omeros Corporation

发明人： W. Jason Cummings ,  Gregory A. Demopulos ,  Thomas A. Dudler ,  Larry W. Tjoelker ,  Christi L. Wood ,  Munehisa Yabuki

IPC分类号： A61K39/395 ,  B82Y25/00 ,  C01F17/206 ,  C07K16/40 ,  C09K11/77 ,  C12N9/64 ,  H01F1/00 ,  A61K39/00

CPC分类号： A61K39/3955 ,  B82Y25/00 ,  C01F17/206 ,  C07K16/40 ,  C09K11/77 ,  C09K11/7728 ,  C12N9/6424 ,  C12Y304/21104 ,  H01F1/0054 ,  A61K39/00 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C01P2002/54 ,  C01P2002/84 ,  C01P2004/64 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92

摘要： The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.

公开(公告)号：US12116413B2

公开(公告)日：2024-10-15

申请号：US16744734

申请日：2020-01-16

申请人： Amgen, Inc.

发明人： Shaw-Fen Sylvia Hu ,  Ian Nevin Foltz ,  Chadwick Terence King ,  Yang Li ,  Taruna Arora

IPC分类号： A61K39/00 ,  C07K14/71 ,  C07K16/18 ,  C07K16/28 ,  C07K16/40

CPC分类号： C07K16/2863 ,  C07K14/71 ,  C07K16/18 ,  C07K16/40 ,  A61K2039/505 ,  C07K16/28 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/32 ,  C07K2317/34 ,  C07K2317/53 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/75 ,  C07K2317/92 ,  C07K2319/30

摘要： The present invention provides compositions and methods relating to or derived from antigen binding proteins activate FGF21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) β-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising β-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to (i) β-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising β-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. Other embodiments provide nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.

公开(公告)号：US20240336701A1

公开(公告)日：2024-10-10

申请号：US18427264

申请日：2024-01-30

申请人： Novartis AG

发明人： Michael DIDONATO ,  Christoph ERKEL ,  Anna Galkin ,  Scott Martin GLASER ,  Klaus Felix HARTLEPP ,  Yong JIA ,  Alexandra KRAUS ,  Christian Cho-Hua LEE ,  Sarah Michelle RUE ,  Jian SHI ,  Xenia Karola WEZLER

IPC分类号： C07K16/40 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28

CPC分类号： C07K16/40 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2818 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/55 ,  C07K2317/92

摘要： Provided herein are antibodies or antigen-binding fragments thereof, e.g., monoclonal antibodies or antigen binding fragments thereof, that specifically bind to ENTPD2 (e.g., human ENTPD2 protein), and methods of using these antibodies or antigen-binding fragments. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.